Aurora Cannabis Inc. is open to considering an acquisition offer from a U.S. cannabis company looking to take over the Edmonton-based firm. The announcement came after Curaleaf Holdings Inc. disclosed its intentions to acquire all shares of Aurora, prompting the formation of a special committee by Aurora to review the unsolicited bid.
Should the acquisition proceed, it would result in the formation of a joint cannabis entity operating in 17 countries across Europe, North America, and other global markets, according to Curaleaf. The company, headquartered in Stamford, Conn., and listed on the Toronto Stock Exchange, made its proposal public following unsuccessful attempts to engage in private negotiations with Aurora’s leadership.
Curaleaf CEO Boris Jordan expressed disappointment over Aurora’s reluctance to engage in meaningful discussions after receiving a formal letter of intent on June 23, followed by a subsequent letter on July 7. Despite Aurora’s denial of refusing to consider the offer, Curaleaf expressed readiness to collaborate with Aurora’s board to finalize the transaction swiftly.
Curaleaf proposed an offer of $4 US per share to Aurora shareholders, in addition to $0.75 US cash for each Aurora share. Aurora acknowledged receiving the proposals from Curaleaf but clarified that only the July 7 letter included specific financial terms.
Aurora’s lead independent director maintained communication with Curaleaf’s CEO until July 24, emphasizing Aurora’s focus on executing its business plan in the short to medium term. A special committee of independent directors will now assess the proposal’s viability and its alignment with stakeholders’ interests, with no assurance of a finalized agreement at this stage.
While acknowledging Curaleaf’s interest in the acquisition, Aurora cautioned that the current offer undervalues the long-term potential of its business, as highlighted by TD Cowen analysts. The analysts emphasized Aurora’s market leadership in medical cannabis, robust product portfolio, financial strength, and regulatory expertise, underscoring the company’s capacity to create substantial long-term value.
Curaleaf’s CEO emphasized the value creation potential of merging the companies, citing the synergy between Curaleaf’s global distribution network and Aurora’s prominent international medical cannabis operations. The combined revenue of over $1.5 billion US in the past year and anticipated cost synergies of at least $40 million US annually further support the strategic rationale behind the proposed takeover, offering shareholders an opportunity to leverage a diversified global platform and benefit from U.S. regulatory trends.